The companies will collaborate with AstraZeneca to advance local lab testing for a prostate cancer genomic instability ...

A comprehensive review shows circulating tumour DNA offers powerful prognostic insight across all major mCRPC treatments, but ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

Please provide your email address to receive an email when new articles are posted on . Use of a precision navigator led to significant increase in genomic profiling among men with prostate cancer.

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

A total of 7,201 veterans with metastatic prostate cancer and CGP were identified. There were 2,484 veterans (median [IQR] age, 72 [67-77] years) with synchronous mHSPC and tissue CGP, which were ...

Findings from a study exploring how AI-driven NCCN guideline interpretation can optimize genetic testing and reduce clinician burden in prostate cancer. Keeping pace with rapid updates to NCCN ...

AI-based research identifies ZNF268 as a potential marker of prostate cancer progression, raising hopes for more accurate ...

Veracyte (NasdaqGM:VCYT) reported new phase III data showing its Decipher Prostate Genomic Classifier can guide hormone therapy use with radiation in intermediate-risk prostate cancer. The phase III ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...